A previous study revealed that treatment with cisplatin results in the enhanced expression of cancer stem cell markers—including CD44, α2 integrin subunit, CD117, CD133, and EpCAM—and the upregulation of stem cell factors—such as Nanog and Oct4—in residual ovarian cancer cells in in vitro assays [70]. This evidence concerns the gene CD44 and ovarian carcinoma.